Literature DB >> 24585365

Plasmapheresis combined with rituximab for refractory idiopathic membranous nephropathy.

Ming Wen1, Claudius Küchle, Oliver Sarkar, Lutz Renders, Uwe Heemann, Christoph Schmaderer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24585365     DOI: 10.1007/s11255-014-0673-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  2 in total

1.  Rituximab in idiopathic membranous nephropathy.

Authors:  Piero Ruggenenti; Paolo Cravedi; Antonietta Chianca; Annalisa Perna; Barbara Ruggiero; Flavio Gaspari; Alessandro Rambaldi; Maddalena Marasà; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

2.  Idiopathic membranous nephropathy: diagnosis and treatment.

Authors:  Fernando C Fervenza; Sanjeev Sethi; Ulrich Specks
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

  2 in total
  3 in total

1.  Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine.

Authors:  Takafumi Ito; Kaori Mochizuki; Tomohiro Oka; Ken Hanada; Kazuaki Tanabe
Journal:  Int Urol Nephrol       Date:  2014-10-09       Impact factor: 2.370

2.  Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: A case report.

Authors:  Hui Lu; Zhao Cui; Xu-Jie Zhou; Qi-Zhuang Jin; Xiao-Juan Yu; Su-Xia Wang; Yu Wang; Fu-de Zhou; Ming-Hui Zhao
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

3.  Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study.

Authors:  Bin Shi; Rong-Rong Zhang; Ying Liang; Xin-Hui Wang; Rui Lang; Ren-Huan Yu
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-24       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.